CD4 and neoplasm: Last, NvIH enhanced the fraction of circulating CD4+ and CD8+ T cells and cytokine-secreting (IFN-γ, TNF-α) CD4+ and CD8+ T cells, which contributed to the protective immunity against tumor rechallenge (Fig. 6, H and I).